EP Patent

EP2792359A1 — Treatment of L-DOPA-induced dyskinesia with OPC-14523 or OPC-34712

Assigned to Merz Pharma GmbH and Co KGaA · Expires 2014-10-22 · 12y expired

What this patent protects

The present invention relates to the efficient treatment of an individual afflicted with L-DOPA-induced dyskinesia, which condition typically arises as a consequence of long-term treatment with L-DOPA therapy in Parkinson patients.

USPTO Abstract

The present invention relates to the efficient treatment of an individual afflicted with L-DOPA-induced dyskinesia, which condition typically arises as a consequence of long-term treatment with L-DOPA therapy in Parkinson patients.

Drugs covered by this patent

Patent Metadata

Patent number
EP2792359A1
Jurisdiction
EP
Classification
—
Expires
2014-10-22
Drug substance claim
No
Drug product claim
No
Assignee
Merz Pharma GmbH and Co KGaA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.